Want to see IVA full AI Analyst Report?
IVA Stock Chart & Stats
$5.67
-$0.02(-0.90%)
At close: 4:00 PM EST
$5.67
-$0.02(-0.90%)
Day’s Range― - ―
52-Week Range$2.85 - $7.98
Previous CloseN/A
Volume917.00
Average Volume (3M)1.41M
Market Cap
$1.00B
Enterprise Value$394.42M
Total Cash (Recent Filing)$99.27M
Total Debt (Recent Filing)$59.40M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Sep 25, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding236,280,200
10 Day Avg. Volume1,889,409
30 Day Avg. Volume1,410,168
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-25.46
Price to Sales (P/S)164.91
P/FCF Ratio-7.30
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue87.99
Enterprise Value/Gross Profit249.52
Enterprise Value/Ebitda-1.62
Forecast
1Y Price Target
$15.40Price Target Upside171.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.77
Revenue Forecast (FY)$4.16M
Bulls Say, Bears Say
Bulls Say
Phase III Enrollment Completed & >90% PoweringCompleting NATiV3 enrollment and securing >90% statistical power materially reduces execution and enrollment risk over the next 6–12 months. A fully enrolled, well‑powered pivotal trial makes the scheduled Q4 2026 readout more predictable and lowers the chance of inconclusive results due to underpowering or major delays.
Material Cash Balance From Recent FinancingsA sizeable cash position funded by recent equity and structured financings provides multi‑month runway to advance the pivotal program and regulatory planning. This liquidity supports trial completion, NDA preparation and targeted pre‑commercial investments without immediate dependence on revenue or partnering.
Refinancing Reshaped Capital Structure And Repaid EIB LoansRepaying legacy EIB debt and repurchasing onerous warrants simplifies the capital structure and reduces restrictive terms. New debt and equity raises provide immediate funding while the restructured instruments and bondholder protections improve financing flexibility and lower the probability of legacy anti‑dilution constraints affecting future raises.
Bears Say
Negative Shareholder Equity & Rising DebtA transition to negative equity and materially higher debt levels weakens balance‑sheet resilience and long‑term optionality. This structural leverage increases refinancing needs, elevates covenants and investor sensitivity, and can force dilutive financing or constrained strategic choices if clinical or commercial progress falters.
Persistent Cash Burn And Negative Operating Cash FlowSustained negative operating and free cash flow signals ongoing reliance on external capital to fund R&D and operations. Elevated burn increases the probability of additional financings before commercialization, creating recurring dilution risk and making medium‑term strategy contingent on successful trial outcomes or asset monetization.
Tolerability, Endpoint Variability And Competitive PressureClass‑linked tolerability (weight gain, fluid retention), endpoint placebo variability and active competitors create persistent regulatory and market risks. Even with positive efficacy, safety labels or modest margins versus rivals can restrict adoption, complicate labeling discussions and reduce commercial potential over multiple years.
Inventiva News
IVA FAQ
What was Inventiva SA ADR’s price range in the past 12 months?
Inventiva SA ADR lowest stock price was $2.85 and its highest was $7.98 in the past 12 months.
What is Inventiva SA ADR’s market cap?
Inventiva SA ADR’s market cap is $1.00B.
When is Inventiva SA ADR’s upcoming earnings report date?
Inventiva SA ADR’s upcoming earnings report date is Sep 25, 2026 which is in 73 days.
How were Inventiva SA ADR’s earnings last quarter?
Inventiva SA ADR released its earnings results on Mar 30, 2026. The company reported -$1.067 earnings per share for the quarter, missing the consensus estimate of -$0.279 by -$0.788.
Is Inventiva SA ADR overvalued?
According to Wall Street analysts Inventiva SA ADR’s price is currently Undervalued.
Does Inventiva SA ADR pay dividends?
Inventiva SA ADR does not currently pay dividends.
What is Inventiva SA ADR’s EPS estimate?
Inventiva SA ADR’s EPS estimate is -0.54.
How many shares outstanding does Inventiva SA ADR have?
Inventiva SA ADR has 236,280,200 shares outstanding.
What happened to Inventiva SA ADR’s price movement after its last earnings report?
Inventiva SA ADR reported an EPS of -$1.067 in its last earnings report, missing expectations of -$0.279. Following the earnings report the stock price went up 1.277%.
Which hedge fund is a major shareholder of Inventiva SA ADR?
Currently, no hedge funds are holding shares in IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inventiva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.40 (171.60% Upside)
$15.40 (171.60% Upside)
Blogger Sentiment
Bullish
IVA Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.21%
12-Months-Change
Fundamentals
Return on Equity
1870.38%
Trailing 12-Months
Asset Growth
138.07%
Trailing 12-Months
Company Description
Inventiva SA ADR
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
IVA Stock 12 Month Forecast
Average Price Target
$15.40
▲(171.60% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Urogen Pharma
―
Maravai Lifesciences Holdings
―
MBX Biosciences, Inc.
―
Ownership Overview
―
Insiders
0.83% Mutual Funds
0.39% Other Institutional Investors
98.65% Public Companies and Individual Investors